使用动态PET对转移性乳腺癌患者进行HER2结合型ABY-025亲和体分子的动力学分析
本研究在16例转移性乳腺癌患者中行动态68Ga-ABY-025 PET,采用不可逆双组织室模型和Patlak图形分析生成参数图像,评估动力学建模对HER2表达的绝对定量能力。结果显示参数图像改善了小肝转移灶的HER2表达表征,Ki与VOI金标准高度一致(R²>0.99),2h和4h SUV与Ki高度相关(R²=0.87和0.95),重复性系数Patlak为30%、双组织室模型为47%。
要点
- 参数图像改善小肝转移灶HER2表达表征,Ki与VOI金标准一致(R²>0.99,p<0.001)。
- 2h和4h SUV与Ki高度相关(R²=0.87和0.95,均p<0.001)。
- 68Ga-ABY-025 PET重复性系数Patlak为30%、双组织室模型为47%。
核心结论
- 68Ga-ABY-025在HER2阳性转移灶中的结合可通过不可逆双组织室模型良好表征,Ki与2h和4h SUV高度相关。
- 动态扫描结合参数图像形成可用于准确评估转移性HER2表达。
研究设计与样本
- 16例转移性乳腺癌患者于注射后0-45分钟行上腹部动态68Ga-ABY-025 PET,其中5例接受两次检查以测试重复性。
- 采用不可逆双组织室模型和Patlak图形分析,以下行主动脉图像衍生输入函数生成示踪剂输送(K1)和不可逆结合(Ki)参数图像。
- 基于感兴趣体积(VOI)的分析用于验证参数图像,SUV由注射后2小时和4小时静态全身图像计算并与Ki比较。
主要发现
- 参数图像改善了较小肝转移灶中HER2表达的表征。
- 参数图像Ki值与VOI金标准高度一致(R²>0.99,p<0.001)。
- 转移灶注射后2小时和4小时SUV与双组织室模型及Patlak法的Ki值均高度相关(R²=0.87和0.95,均p<0.001)。
- 68Ga-ABY-025 PET具有高重测可靠性(Patlak相对重复性系数30%,双组织室模型47%)。
关键数值与推荐
- 参数图像Ki与VOI金标准比较R²>0.99(p<0.001)。
- 2小时和4小时SUV与Ki比较R²=0.87和0.95(均p<0.001)。
- 重测相对重复性系数Patlak为30%、双组织室模型为47%。
临床怎么用
- 动态扫描结合参数图像形成可用于准确评估转移性HER2表达。
局限性
- 检测小肝病灶可能受高背景摄取影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: High expression of human epidermal growth factor receptor type 2 (HER2) represents an aggressive subtype of breast cancer. Anti-HER2 treatment requires a theragnostic approach wherein sufficiently high receptor expression in biopsy material is mandatory. Heterogeneity and discordance of HER2 expression between primary tumour and metastases, as well as within a lesion, present a complication for the treatment and require multiple biopsies. Molecular imaging using the HER2-targeting Affibody peptide ABY-025 radiolabelled with 68Ga-gallium for PET/CT is currently under investigation as a non-invasive tool for whole-body evaluation of metastatic HER2 expression. Initial studies demonstrated a high correlation between 68Ga-ABY-025 standardized uptake values (SUVs) and histopathology. However, detecting small liver lesions might be compromised by high background uptake. This study aimed to explore the applicability of kinetic modelling and parametric image analysis for absolute quantification of 68Ga-ABY-025 uptake and HER2-receptor expression and how that relates to static SUVs. METHODS: Dynamic 68Ga-ABY-025 PET of the upper abdomen was performed 0-45 min post-injection in 16 patients with metastatic breast cancer. Five patients underwent two examinations to test reproducibility. Parametric images of tracer delivery (K1) and irreversible binding (Ki) were created with an irreversible two-tissue compartment model and Patlak graphical analysis using an image-derived input function from the descending aorta. A volume of interest (VOI)-based analysis was performed to validate parametric images. SUVs were calculated from 2 h and 4 h post-injection static whole-body images and compared to Ki. RESULTS: Characterization of HER2 expression in smaller liver metastases was improved using parametric images. Ki values from parametric images agreed very well with VOI-based gold standard (R2 > 0.99, p < 0.001). SUVs of metastases at 2 h and 4 h post-injection were highly correlated with Ki values from both the two-tissue compartment model and Patlak method (R2 = 0.87 and 0.95, both p < 0.001). 68Ga-ABY-025 PET yielded high test-retest reliability (relative repeatability coefficient for Patlak 30% and for the two-tissue compartment model 47%). CONCLUSION: 68Ga-ABY-025 binding in HER2-positive metastases was well characterized by irreversible two-tissue compartment model wherein Ki highly correlated with SUVs at 2 and 4 h. Dynamic scanning with parametric image formation can be used to evaluate metastatic HER2 expression accurately.
引用
- Alhuseinalkhudhur A, Lubberink M, Lindman H, et al. Kinetic analysis of HER2-binding ABY-025 Affibody molecule using dynamic PET in patients with metastatic breast cancer. EJNMMI Res. 2020. PMID: 32201920. doi:10.1186/s13550-020-0603-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。